183 related articles for article (PubMed ID: 2069399)
1. [Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA].
Okamura Y; Takatsuka Y; Katoh T; Tsumura I; Kobayakawa K; Kawahara T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1279-85. PubMed ID: 2069399
[TBL] [Abstract][Full Text] [Related]
2. [Study on the clinical usefulness of NCC-ST-439 in breast cancer].
Takahashi H; Nakanishi K; Taguchi K; Hasumi T; Hamada H; Sasaki F; Hata Y; Uchino J
Gan To Kagaku Ryoho; 1991 Feb; 18(2):245-9. PubMed ID: 1992918
[TBL] [Abstract][Full Text] [Related]
3. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients].
Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T
Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168
[TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
[TBL] [Abstract][Full Text] [Related]
5. [Clinical evaluation of tumor markers in breast cancer patients].
Ito T; Tanaka S; Ban K; Sakai N; Oshita H; Oiwa T; Kanno A; Kashizuka T
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of serum NCC-ST 439 as a tumor marker for colorectal cancer].
Yamaguchi A; Kurosaka Y; Ohta N; Kamata T; Ishida T; Nishimura G; Katoh M; Kosaka T; Yonemura Y; Miyazaki I
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2645-50. PubMed ID: 2549882
[TBL] [Abstract][Full Text] [Related]
8. Expression of tumour markers CA50, CEA and TPA in female breast carcinoma as related to histopathological findings and survival.
Eskelinen M; Lipponen P; Syrjänen K
Anticancer Res; 1992; 12(1):91-5. PubMed ID: 1567186
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis of skeletal metastases by serum tumor markers].
Shinozaki T; Chigira M
Nihon Seikeigeka Gakkai Zasshi; 1991 Aug; 65(8):441-6. PubMed ID: 1720162
[TBL] [Abstract][Full Text] [Related]
10. The tumor markers CEA, TPA and CA 19-9 in gastric cancer.
Putzki H; Reichert B; Jablonski M; Heymann H
Dtsch Z Verdau Stoffwechselkr; 1988; 48(3-4):145-8. PubMed ID: 3234297
[TBL] [Abstract][Full Text] [Related]
11. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
Kaneko Y; Imoto S; Kasakura S
Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
[TBL] [Abstract][Full Text] [Related]
12. [Study on carbohydrate antigen NCC-ST-439 in breast cancer].
Suzuki S; Nihei M; Nomizu T; Watanabe T; Kimijima I; Tsuchiya A; Abe R
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):1019-26. PubMed ID: 2202768
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evaluation of four tumor markers (CEA, TPA, CA50 and CA72-4) in colorectal cancer].
Koizumi F; Odagiri H; Fujimoto H; Kawamura T; Ishimori A
Rinsho Byori; 1992 May; 40(5):523-8. PubMed ID: 1507478
[TBL] [Abstract][Full Text] [Related]
14. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
15. [The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer].
Schatz C; von Lieven H; Mulders M; Rowold J; Stracke H; Müller H; Grebe SF; Schatz H
Wien Klin Wochenschr; 1985 Dec; 97(23):873-9. PubMed ID: 3878042
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon.
von Kleist S; Hesse Y; Kananeeh H
Anticancer Res; 1996; 16(4B):2325-31. PubMed ID: 8694564
[TBL] [Abstract][Full Text] [Related]
17. Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients.
Paulick R; Caffier H; Paulick M
Cancer Detect Prev; 1987; 10(3-4):197-203. PubMed ID: 3568016
[TBL] [Abstract][Full Text] [Related]
18. [Pretreatment evaluation of CA 72.4 in patients with carcinoma of the stomach (0-IV stage) versus CEA, TPA, CA 19-9, FER].
Buda F; Aragona P; Giani G; Sisto R; Di Nardo G; Binotto F; Gangemi P; De Zerbi T; Gentile G; Papadia A
G Ital Oncol; 1989; 9(2-3):67-72. PubMed ID: 2767730
[TBL] [Abstract][Full Text] [Related]
19. How can treatment response be measured in breast cancer patients?
van Dalen A; van der Linde DL; Heering KJ; van Oudalblas AB
Anticancer Res; 1993; 13(5C):1901-4. PubMed ID: 8267398
[TBL] [Abstract][Full Text] [Related]
20. [Tumor markers. I. Their significance in the preoperative assessment of lung neoplasms].
Ratto GB; Capponi G; De Grandi R; Augeri C; Secco GB; Fardelli R
Minerva Chir; 1990 Oct; 45(20):1265-72. PubMed ID: 1964495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
